

Format for ANSWERING REVIEWERS



June 16, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 19284-review.doc).

Title:

Author: Amalia Palacios-Eito, Sonia García-Cabezas.

Name of Journal: *World Journal of Clinical Oncology*.

ESPS Manuscript NO: 19284

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) RESPONSE TO REVIEWER 1 (00736646):

Major revision:

This paper is well-written. However, very important two concepts related to oligometastases were lacked in this Editorial. The authors should explain these two concepts in this Editorial according to science history and scientists' ethics. One is oligo-recurrence. This concept was proposed by Niibe Y et al. in 2006. Cancer patients have 1-5 metastatic or recurrent lesions with controlled primary lesions, which were treated by local therapy. This point is primary lesions have been controlled. The authors should read and cite the review article " Niibe Y et al. Oligometastases and Oligo-recurrence: the New Era of Cancer Therapy. Jpn J Clin Oncol 40: 107-111, 2010." This concept is milestone of oligometastases history. Because, oligo-recurrence is the most favorable prognostic factor among oligometastases (Niibe Y. Ann Oncol 29(Supple),v29-v29 2014). Second, the concept of sync-oligometastases is also very important. Sync-oligometastases was proposed by Niibe Y and Chang JY (Niibe Y and Chang JY. Pulm Med 2012: 261096, 2012). This concept means that cancer patients have 1-5 metastatic or recurrent lesions with active primary lesions, both of which were treated by local therapy. The authors should cite this review and explain the concept of sync-oligometastases. Last, Niibe Y and Chang JY were the first professionals of definition that oligometastases meant only 1-5 metastatic or recurrent lesions (Niibe Y and Chang JY. Pulm Med 2012: 261096, 2012). Thank you for reviewing significant and valuable Editorial.

The two concepts, oligo-recurrence and sync-oligometastases have been explained and the suggested articles have been cited.

(2) RESPONSE TO REVIEWER 2 (00289473):

Minor revision:

Minor comments. The paper should be further improved by including a table with a list of main findings of oligometastatic signature.

We have included a table 1, summary of selected series of SBRT.

(3) RESPONSE TO REVIEWER 3 (00061689):

Very nice editorial Please correct typos: - It may therefore be stated that the oligometastatic STATUS exists, and that a proportion of patients with disseminated disease may be cured. - These are the only databases of miRNAs associated to oligoMETAstases available to date).

Typos have been corrected.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Clinical Oncology*.

Sincerely yours,



Peter Laszlo LAKATOS, MD, PhD

1st Dept. of Medicine

Semmelweis University

Budapest, Koranyi 2A

H-1083-Hungary

Fax: +36-1-313-0250

E-mail: kislakpet@bell.sote.hu